Oncology and Cancer Care for Older Adults

Cancer is not an equal-opportunity disease by age. Adults 65 and older account for approximately 60 percent of all new cancer diagnoses in the United States, according to the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program. That single statistic reshapes how oncology needs to be thought about — not as a middle-aged person's medical crisis, but as one of the defining health challenges of the elder care landscape. This page covers what oncology care looks like for older adults, how treatment decisions differ from younger patients, and where the planning and support systems intersect with broader elder care for chronic conditions.

Definition and scope

Oncology and cancer care for older adults refers to the specialized clinical and supportive management of malignant disease in patients typically 65 and older — a group whose cancer biology, physiological reserves, and social circumstances differ in medically meaningful ways from younger adults.

The scope extends well beyond the oncologist's office. Older cancer patients often carry 2 or more comorbid conditions — hypertension, diabetes, heart disease, chronic kidney disease — that directly constrain what chemotherapy regimens or surgical approaches are safe. They may be managing 5 or more medications simultaneously, which creates real interaction risks when cytotoxic drugs enter the picture. (See medication management for elderly for a closer look at polypharmacy risks.) Cognitive status, physical function, social support, and nutritional baseline all factor into prognosis and treatment tolerance in ways that a standard oncology protocol wasn't designed to weigh.

Geriatric oncology emerged as a subspecialty specifically because of this gap. The field applies structured tools — the Comprehensive Geriatric Assessment (CGA) is the most widely validated instrument — to measure functional reserves before treatment decisions are made.

How it works

The treatment pathway for an older cancer patient runs through roughly the same sequence as for any adult — diagnosis, staging, multidisciplinary tumor board review, treatment selection, and follow-up — but with an additional layer of geriatric evaluation woven in.

A Comprehensive Geriatric Assessment typically measures:

1. Functional status — Activities of Daily Living (ADLs) and Instrumental Activities of Daily Living (IADLs), often using the Katz Index or Lawton Scale
2. Cognitive function — Mini-Cog or Montreal Cognitive Assessment (MoCA) screening
3. Nutritional status — weight loss over 6 months, Mini Nutritional Assessment score
4. Comorbidity burden — Charlson Comorbidity Index or Cumulative Illness Rating Scale
5. Mobility and fall risk — Timed Up and Go (TUG) test, gait speed measurement
6. Social support and living situation — who provides care, transportation access, caregiver capacity
7. Psychological status — depression screening using the Geriatric Depression Scale

The American Society of Clinical Oncology (ASCO) recommends CGA-based evaluation for older adults before initiating chemotherapy, citing evidence that it predicts treatment toxicity better than performance status scores alone. ASCO's 2018 guideline update specifically identified CGA as a standard of care consideration for patients 65 and older receiving chemotherapy.

Advance care planning runs parallel to this clinical process — documenting goals of care, healthcare proxy designations, and treatment preferences before a crisis forces those conversations under pressure.

Common scenarios

Three patterns show up with particular frequency in older adult oncology:

Early-stage solid tumor in a functionally robust older adult. A 72-year-old woman with stage II breast cancer and no significant comorbidities may tolerate surgery, radiation, and hormonal therapy comparably to a 55-year-old. Age alone is not a contraindication, and undertreating fit older adults is a documented clinical error.

Aggressive cancer in a frail or cognitively impaired patient. A patient with moderate dementia and limited functional reserve who receives a pancreatic cancer diagnosis presents a fundamentally different decision set. Standard chemotherapy toxicity risk is substantially elevated, and goals of care shift toward quality of life, symptom management, and hospice and palliative care — sometimes immediately.

Incidental or slow-growing cancer managed with active surveillance. Low-grade prostate cancer in a man in his early 80s often warrants watchful waiting rather than intervention. The cancer may never become symptomatic within the patient's life expectancy, and treatment side effects — urinary incontinence, sexual dysfunction, fatigue — could significantly reduce quality of life without adding meaningful survival benefit.

Family caregivers navigating these scenarios carry a substantial coordination burden. The family caregiver guide addresses how to manage that load without losing track of the patient's own expressed preferences.

Decision boundaries

The hardest decisions in older adult oncology cluster around two tensions: curative intent versus comfort-focused care, and aggressive treatment versus functional preservation.

Curative vs. palliative intent is not strictly age-dependent, but functional status and life expectancy weigh heavily. Oncologists increasingly use tools like the ePrognosis calculator (developed at UCSF) to estimate 1- and 5-year mortality probabilities in older adults independent of cancer — which clarifies whether aggressive treatment is likely to extend life meaningfully or primarily produce toxicity.

Treatment intensity vs. function preservation is where the contrast between geriatric oncology and standard oncology is sharpest. A younger patient might accept significant short-term functional decline for a higher cure rate. An 80-year-old living independently may reasonably prioritize maintaining that independence over a modest improvement in survival odds. Neither choice is wrong; they reflect different, legitimate value systems.

Cognitive impairment adds a third boundary: decision-making capacity. When a patient cannot meaningfully participate in informed consent, a designated healthcare proxy — established through advance care planning — becomes the decision-maker. Without that documentation, families and clinicians face legal and ethical complexity that rarely resolves quickly or cleanly.

The oncology team, primary care physician, geriatrician, palliative care specialist, and care coordination and case management professionals ideally work as an integrated unit — because the decisions are rarely purely medical, and they are rarely made just once.